Head-to-head comparison of 68 Ga-PSMA-11 PET/CT and 68 Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies.

Purpose: Our meta-analysis aimed to evaluate the diagnostic performance of ⁶⁸ Ga-PSMA-11 PET/CT vs. ⁶⁸ Ga-PSMA-11 PET/MRI for biochemical recurrence of prostate cancer.
Methods: We searched for relevant articles in PubMed and Embase until February 2022. Studies evaluating head-to-head comparison of ⁶⁸ Ga-PSMA-11 PET/CT and ⁶⁸ Ga-PSMA-11 PET/MRI in men with prostate cancer biochemical recurrence were included. The quality of each study was assessed using the Quality Assessment of Diagnostic Performance Studies-2 (QUADAS-2) tool.
Results: A total of 5 studies with 219 patients were included in the analysis. The pooled overall detection rates of ⁶⁸ Ga-PSMA-11 PET/CT and ⁶⁸ Ga-PSMA-11 PET/MRI in detecting recurrent PCa after definitive treatment were 0.89 (95% CI: 0.65-1.00), 0.92 (95% CI: 0.77-1.00), while the detection rates were 0.20 (95% CI: 0.05-0.41) and 0.29 (95% CI: 0.10-0.53) in local recurrence, 0.51 (95% CI: 0.33-0.69) and 0.52 (95% CI: 0.44-0.61) in lymph node metastasis, 0.18 (95% CI: 0.07-0.33) and 0.20 (95% CI: 0.09-0.35) in bone metastasis. There was no significant difference between the two imaging modalities in the overall detection rate (P = 0.82). In addition, detection rates were also not significantly different in local recurrence, lymph node metastasis, or bone metastasis (P = 0.54, 1.00, 0.82).
Conclusions: ⁶⁸ Ga-PSMA-11 PET/CT and ⁶⁸ Ga-PSMA-11 PET/MRI seem to have equivalent performance in detecting biochemical recurrence in prostate cancer. However, the results of the meta-analysis were drawn from studies with small samples. Further larger studies in this setting are warranted.
(© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)